Share on StockTwits

Research analysts at Oppenheimer started coverage on shares of Ocular Therapeutix (NASDAQ:OCUL) in a report released on Tuesday, reports. The firm set an “outperform” rating on the stock.

Ocular Therapeutix (NASDAQ:OCUL) opened at 14.33 on Tuesday. Ocular Therapeutix has a 52 week low of $11.90 and a 52 week high of $15.249. The stock has a 50-day moving average of $13.32 and a 200-day moving average of $13.32. The company’s market cap is $294.8 million.

Separately, analysts at RBC Capital initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday. They set an “outperform” rating and a $21.00 price target on the stock.

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.